Zinc Sulfate Monohydrate Market

Zinc sulfate monohydrate API market is projected to grow at a CAGR of 6.3% between 2025 and 2035. The rising prevalence of zinc deficiency disorders, along with increased usage in parenteral and oral nutritional supplements, is fueling demand for pharmaceutical-grade zinc sulfate monohydrate. The compound is widely utilized in human and veterinary pharmaceuticals due to its high bioavailability, affordability, and efficacy in treating and preventing zinc deficiencies.

Among the market segments, pharmaceuticals represent the largest share, accounting for over 50% of global demand in 2023. Zinc sulfate monohydrate is a key ingredient in zinc supplements, especially in developing countries where malnutrition is prevalent. Additionally, the Veterinary segment is experiencing a steady uptick, driven by increased attention to animal nutrition and health in the livestock industry.

Geographically, Asia Pacific dominates the global market, with India emerging as a key contributor due to its robust pharmaceutical manufacturing base, favorable government initiatives, and the growing export of generic APIs. The country’s low-cost production and large pool of skilled labor have positioned it as a leading supplier of zinc-based APIs to global markets. Other notable countries include China and Brazil, where demand is being driven by both domestic consumption and global API exports.

Key players shaping the Zinc Sulfate Monohydrate API landscape include Jost Chemical Co., Sulux Phosphates Ltd., Alpha Chemicals, Merck KGaA, and Rech Chemical Co. Ltd. These companies are focusing on capacity expansion, product quality enhancement, and strategic partnerships with pharmaceutical firms to strengthen their market presence. Increasing regulatory scrutiny on API manufacturing standards is also prompting players to invest in advanced production technologies and quality certifications to meet global compliance requirements.